XML 35 R20.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
The Company's Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Company's Finance Receivables segment does not have any revenues received from contracts with customers.
The following table provides the contract revenue recognized by revenue source for the years ended December 31, 2025 and 2024 (in thousands):
December 31,
20252024
Pharmaceutical Development Segment
License Agreement$— $49 
Pharmaceutical development and other2,153 3,567 
Total contract revenue$2,153 $3,616 
The Company’s contract liabilities represent advance consideration received from customers and are recognized as revenue when the related performance obligation is satisfied.
The Company’s contract liabilities are presented as deferred income in the consolidated balance sheets (in thousands):
December 31, 2025
Pharmaceutical Development Segment
Beginning balance$1,500 
Additions to deferred income1,800 
Income recognized (1)
(3,300)
Ending balance$— 
(1) Included as a component on the gain of sale of MOD3 assets
The Company did not have any contract assets as of December 31, 2025 or December 31, 2024.